Isoflurane-induced preconditioning is attenuated by diabetes

Area of Science:

• Cardiology
• Anesthesiology
• Metabolic Research

Background:

• Volatile anesthetics like isoflurane can precondition the heart, reducing infarct size during ischemia-reperfusion injury.
• Mitochondrial ATP-regulated K(+) channels are implicated in anesthetic preconditioning, with activity stimulated by anesthetics but attenuated by hyperglycemia.
• Diabetes mellitus is characterized by hyperglycemia, potentially interfering with cardioprotective mechanisms.

Purpose of the Study:

• To investigate the hypothesis that diabetes mellitus interferes with isoflurane-induced myocardial preconditioning.
• To determine the impact of diabetes and varying isoflurane concentrations on infarct size in a canine model.

Main Methods:

• A canine model of myocardial infarction was established using coronary artery occlusion and reperfusion.
• Dogs were assigned to groups receiving different end-tidal isoflurane concentrations (0, 0.32, 0.64%) in the presence or absence of experimentally induced diabetes.
• Myocardial infarct size was quantified using triphenyltetrazolium staining, and blood glucose levels were monitored.

Main Results:

• Isoflurane significantly reduced infarct size in non-diabetic dogs in a dose-dependent manner.
• Diabetes alone did not alter infarct size but abolished the protective effect of 0.32% isoflurane.
• The cardioprotective effect of 0.64% isoflurane was preserved in diabetic dogs.
• In diabetic dogs, infarct size correlated with blood glucose, but this relationship was abolished by higher isoflurane concentrations.

Conclusions:

• Diabetes mellitus significantly interferes with the cardioprotective effects of lower concentrations of isoflurane.
• Higher concentrations of isoflurane can overcome the negative impact of diabetes on anesthetic preconditioning.
• Blood glucose levels and end-tidal isoflurane concentrations are critical determinants of infarct size during anesthetic-induced preconditioning.